Jazz Pharmaceuticals (JAZZ) Citigroup’s Biopharma Back to School Summit 2026 summary

Commercial performance and portfolio evolution

• Achieved record $1.2 billion in Q2 revenue, with double-digit growth across all key brands.

• XYWAV posted 13% growth and strong net patient adds, maintaining resilience despite competition.

• Portfolio has evolved from sleep to include oncology and epilepsy, with a strategic focus on rare diseases.

• Recent launches like dordaviprone and Zepzelca, plus the outlook for Ziihera, prompted raised 2026 guidance.

• Corporate development deals are strengthening positions in epilepsy and rare oncology.

Ziihera launch and growth strategy

• Ziihera launched in first-line GEA with a favorable label and permanent J-code, aiming for rapid academic and community adoption.

• Peak sales projections for Ziihera raised to $3–$5 billion, driven by expansion into breast, colorectal, and lung cancers.

• Phase III metastatic breast cancer data expected in late 2027 or early 2028.

• Quarterly revenue reporting will track GEA launch progress, with focus on both academic and community uptake.

• Triplet regimen expected to be the primary choice, offering survival benefits and broad patient eligibility.

Zepzelca and epilepsy franchise

• Zepzelca exceeded $100 million in Q2, with 42% revenue growth; first-line maintenance segment now drives growth.

• Epidiolex delivered 16% revenue and 14% volume growth in Q2, with continued expansion in adult and long-term care segments.

• Capsule formulation for Epidiolex expected to improve tolerability and expand adult patient pool.

• Four new clinical studies for Epidiolex target additional indications, leveraging exclusivity through the late 2030s.

• Recent Actio acquisition brings ABS-1230 for KCNT1 epilepsy, leveraging existing epilepsy infrastructure.